Yifan Pharmaceutical Co., Ltd.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
1/10
|
145.1 | 69.4 | 109.08% | 0 | 0% |
| P/S |
|
4.86 | 6.51 | -25.31% |
|
|
| P/BV |
|
2.01 | 3.96 | -49.19% |
|
|
| P/FCF |
|
0 | 0 | 0% |
|
|
| Ev/Ebitda |
|
124.43 | 11.85 | 950.18% |
|
|
| Ev/S |
|
4.88 | 5.98 | -18.35% |
|
|
| Ev/FCF |
|
0 | 0 | 0% |
|
|
| E/P |
|
0.0076 | 0.0396 | -80.81% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
2/10
|
7.35 | 20.39 | -63.97% | 16.06 | -54.27% |
| ROE |
|
0.74 | 11.95 | -93.81% |
|
|
| ROA |
|
0.38 | 5.4 | -92.97% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
3.48 | 16.23 | -78.56% |
|
|
| ROCE |
|
0 | 0 | 0% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
0/10
|
8.16 | 14.63 | -44.21% | 5.44 | +50.06% |
| Nеt Debt/Ebitda |
|
0 | 0 | 0% |
|
|
| Debt/Ratio |
|
0 | 0 | 0% |
|
|
| Debt/Equity |
|
0 | 0 | 0% |
|
|
| Debt/Net Income |
|
17.21 | 3.6 | 378.08% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.83 | -100% | 0.9007 | -100% |
| Number of years of dividend growth |
|
0 | 1.44 | -100% | ||
| DSI |
|
0.8571 | 0.9113 | -5.94% |
|
|
| Average dividend growth |
|
-10.83 | 10.4 | -204.21% |
|
|
| Average percentage for 5 years |
|
0.9007 | 1.14 | -21.13% |
|
|
| Average percentage for payments |
|
115.86 | 44.8 | 158.62% |
|
|
| Difference from average difference in sector |
|
-1.83 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
-21.57 | 61.43 | -135.11% | ||
| Growth impulse Ebitda in 5 years |
|
-55.91 | 158.62 | -135.25% | ||
| Growth impulse Net Income in 5 years |
|
-161 | 66.93 | -340.55% | ||
| Growth impulse FCF in 5 years |
|
-318.5 | 248.41 | -228.22% | ||
| Growth impulse EPS in 5 years |
|
92.78 | 73.29 | 26.59% |
IP Score
3.58/10
